Predicting response to systemic treatments: Learning from the past to plan for the future

Breast

Volumn 14, Issue 6, 2005, Pages 582-593

  Regan, Meredith M ^a   Gelber, Richard D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adjuvant therapy; Breast cancer; Chemotherapy; Estrogen receptors; Predictive factors; Progesterone receptors; STEPP; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; PROGESTERONE RECEPTOR; TAMOXIFEN;

AGE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; LOW DRUG DOSE; META ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

EID: 27244439432     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.08.021     Document Type: Article

References (19)

1. A. Goldhirsch J.H. Glick R.D. Gelber A.S. Coates B. Thürlimann J. Senn H.-J. Meeting highlights: International consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 2005 1569-1583
2. M. Colleoni M. Bonetti A.S. et al. Coates for the International Breast Cancer Study Group Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors J Clin Oncol 18 2000 584-590
3. M. Colleoni S. Gelber A.S. et al. Coates for the International Breast Cancer Study Group Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer J Clin Oncol 19 2001 4141-4149
4. M. Colleoni D. Zahrieh R.D. et al. Gelber Preoperative systemic treatment: Prediction of responsiveness Breast 12 2003 538-542
5. C.M. Perou et al. Molecular portraits of human breast tumours Nature 406 2000 747-752
6. M. Bonetti R.D. Gelber A graphical method to assess treatment - covariate interactions using the Cox model on subsets of the data Stat Med 19 2000 2595-2609
7. M. Bonetti R.D. Gelber A. Goldhirsch M. Castiglione-Gertsch A.S. Coates for the International Breast Cancer Study Group Innovative strategies of adjuvant treatments. Features that predict responsiveness to chemotherapy and endocrine therapies Breast 10 2001 147-157
8. M. Bonetti R.D. Gelber Patterns of treatment effects in subsets of patients in clinical trials Biostatistics 5 2004 465-481
9. A.S. Coates A. Goldhirsch R.D. Gelber Overhauling the breast cancer overview: Are subsets subversive? Lancet Oncol 3 2002 525-526
10. International Breast Cancer Study Group Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial J Natl Cancer Inst 94 2002 1054-1065
11. International Breast Cancer Study Group Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients J Clin Oncol 15 1997 1385-1394
12. B. Fisher J.H. Jeong J. Bryant S. Anderson J. Dignam E.R. Fisher et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials Lancet 364 2004 858-868
13. M. Colleoni S. Li R.D. Gelber et al. on behalf of the International Breast Cancer Study Group (IBCSG) Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor Ann Oncol 16 2005 716-725
14. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: An overview of the randomised trials Lancet 352 1998 930-942
15. Albain K, Barlow W, O'Malley F, et al. for The Breast Cancer Intergroup of North America. Concurrent versus sequential chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus tamoxifen alone for postmenopausal, node-positive, estrogen and/ or progesterone receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). San Antonio Breast Cancer Symposium, 2004 December 8-11; San Antonio, Texas (new abstr. 37).
16. D.A. Berry C. Cirrincione I.C. Henderson et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen receptor-negative, node-positive breast cancer: 20-year experience of the CALGB & US Breast Intergroup Breast Cancer Res Treat 88 Suppl 1 2004 S17
17. M.E. Lippman J.C. Allegra Quantitative estrogen receptor analyses: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval Cancer 46 1980 2829-2834
18. H. Roché P. Fumoleau M. Spielmann J.L. Canon T. Delozier P. Kerbrat et al. Five years analysis of the pacs 01 trial: 6 cycles of fec100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer Breast Cancer Res Treat 88 suppl 1 2004 S16
19. D. Crivellari K. Price R.D. Gelber A et al. djuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21 year results of International Breast Cancer Study Group Trial IV J Clin Oncol 21 2003 4517-4523